

論 文

英文：査読誌

1. The suppressive effect on CD4 T-cell alloresponse against endothelial HLA-DR via PD-L1 induced by anti-A/B ligation. Iwasaki K, Hamana H, Kishi H, Yamamoto T, Hiramitsu T, Okada M, Takeda A, Tomosugi T, Narumi S, Watarai Y, Miwa Y, Okumura M, Matsuoka Y, Horimi K, Muraguchi A, Kobayashi T *Clin, Exp. Immunol.* 2020
2. Interferon- γ -induced HLA Class II expression on endothelial cells is decreased by inhibition of mTOR and HMG-CoA reductase. Maenaka A, Iwasaki K, Ota A, Miwa Y, Ohashi W, Horimi K, Matsuoka Y, Ohnishi M, Uchida K, Kobayashi T. *FEBS Open Bio.* 2020 May;10(5):927-936.
3. Inferior Long-Term Graft Survival of Suboptimal Kidneys After Living Donor Kidney Transplantation. Yamanaga S, Freise CE, Stock PG, Rosario A, Fernandez D, Kobayashi T, Tavakol M, Kang SM. *Transplant Proc.* 2020 May 20:S0041-1345(19)31769-5.
4. Clostridium butyricum Modulates the Microbiome to Protect Intestinal Barrier Function in Mice with Antibiotic-Induced Dysbiosis. Hagihara M, Kuroki Y, Ariyoshi T, Higashi S, Fukuda K, Yamashita R, Matsumoto A, Mori T, Mimura K, Yamaguchi N, Okada S, Nonogaki T, Ogawa T, Iwasaki K, Tomono S, Asai N, Koizumi Y, Oka K, Yamagishi Y, Takahashi M, Mikamo H. *iScience.* 2020 Jan 24;23(1):100772.

5. Suppressive Effect of Everolimus on IL-2, IL-10, IL-21, and IFN γ Levels: Implications for the Successful Minimization of Calcineurin Inhibitor Use in Transplantation. Iwasaki K, Kitahata N, Miwa Y, Uchida K, Matsuoka Y, Horimi K, Kobayashi T. *Ther Drug Monit.* 2019 Jun;41(3):371-375.
6. Everolimus-based Immunosuppression Possibly Suppresses Mean Fluorescence Intensity Values of De Novo Donor-specific Antibodies After Primary Kidney Transplantation. Narumi S, Watarai Y, Goto N, Hiramitsu T, Tsujita M, Okada M, Futamura K, Tomosugi T, Nishihira M, Sakamoto S, Kobayashi T. *Transplant Proc.* 2019 Jun;51(5):1378-1381.
7. Lower incidence of de novo donor-specific antibodies against HLA-DR in ABO-incompatible renal transplantation. Okada M, Watarai Y, Iwasaki K, Futamura K, Yamamoto T, Hiramitsu T, Tsujita M, Goto N, Narumi S, Takeda A, Kobayashi T. *Hum Immunol.* 2019 Mar;80(3):169-175.
8. Current activity of xenotransplantation in Japan. Kobayashi T, Miyagawa S. *Xenotransplantation.* 2019 Jan;26(1):e12487.
9. Inferior long-term graft survival after end-to-side reconstruction for two renal arteries in living donor renal transplantation. Yamanaga S, Rosario A, Fernandez D, Kobayashi T, Tavakol M, Stock PG, Kang SM. *PLoS One.* 2018 Jul 11;13(7):e0199629.
10. Increased CD40L+PD-1+ follicular helper T cells (Tfh) as a biomarker for predicting calcineurin inhibitor sensitivity against Tfh-mediated B-cell activation/antibody production after kidney transplantation. Iwasaki K, Kitahata N, Hiramitsu T, Yamamoto T, Noda T, Okada M, Narumi S, Watarai Y, Miwa Y, Uchida K, Matsuoka Y, Horimi K, Kobayashi T. *Int Immunol.* 2018 Jul 24;30(8):345-355.

11. Peripheral blood immune response-related gene analysis for evaluating the potential risk of chronic antibody-mediated rejection. Yamamoto T, Iwasaki K, Murotani K, Takeda A, Futamura K, Okada M, Tsujita M, Hiramitsu T, Goto N, Narumi S, Watarai Y, Morozumi K, Uchida K, Kobayashi T. *Hum Immunol*. 2018 Jun;79(6):432-438.
12. Favorable results in ABO-incompatible renal transplantation without Bcell-targeted therapy: Advantages and disadvantages of rituximab pretreatment. Okada M, Watarai Y, Iwasaki K, Murotani K, Futamura K, Yamamoto T, Hiramitsu T, Tsujita M, Goto N, Narumi S, Takeda A, Morozumi K, Uchida K, Kobayashi T. *Clin Transplant*. 2017 Oct;31(10).
13. Surgical Techniques and Procedures for Kidney Transplant Recipients With Severe Atherosclerosis. Koji Nanmoku, Yoshihiko Watarai, Shunji Narumi, Norihiko Goto, Takayuki Yamamoto, Makoto Tsujita, Takahisa Hiramitsu, Akio Katayama, Takaaki Kobayashi, Kazuharu Uchida. *Exp. Clinic. Transplant*. 2017 Dec;15
14. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report. Yamamoto T, Watarai Y, Futamura K, Okada M, Tsujita M, Hiramitsu T, Goto N, Narumi S, Takeda A, Kobayashi T. *Transplant Proc*. 2017 Jan - Feb;49
15. Regulation of Clinical Xenotransplantation-Time for a Reappraisal. Cooper DKC, Pierson RN 3rd, Hering BJ, Mohiuddin MM, Fishman JA, Denner J, Ahn C, Azimzadeh AM, Buhler LH, Cowan PJ, Hawthorne WJ, Kobayashi T, Sachs DH. *Transplantation*. 2017 Aug;101(8):1766-1769.

16. Negative regulation of HLA-DR expression on endothelial cells by anti-blood group A/B antibody ligation and mTOR inhibition. Iwasaki K, Miwa Y, Uchida K, Kodera Y, Kobayashi T. *Transpl Immunol.* 2017 Feb;40:22-30.
17. MiR-142-5p and miR-486-5p as biomarkers for early detection of chronic antibody-mediated rejection in kidney transplantation. Iwasaki K, Yamamoto T, Inanaga Y, Hiramitsu T, Miwa Y, Murotani K, Narumi S, Watarai Y, Katayama A, Uchida K, Kobayashi T. *Biomarkers.* 2017 Feb;22(1):45-54.
18. A Single Perioperative Injection of Dexamethasone Decreases Nausea, Vomiting and Pain After Laparoscopic Donor Nephrectomy. Yamanaga S, Posselt AM, Freise CE, Kobayashi T, Tavakol M, Kang SM. *J Transplant.* 2017 Jan 22.
19. 5-year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: Retrospective single center assessment. Hiramitsu T, Okada M, Futamura K, Yamamoto T, Tsujita M, Goto N, Narumi S, Watarai Y, Takeda A, Iwasaki K, Uchida K, Kobayashi T. *Int Immunopharmacol.* 2016 Oct;39:192-198.
20. Changes in ABCB1 mRNA Expression in Peripheral Blood Cells before and after Renal Transplantation. Kushihara H, Kuzuya T, Miwa Y, Iwasaki K, Watarai Y, Uchida K, Yamada K, Kobayashi T. *Biol Pharm Bull.* 2016;39(7):1085-90.
21. Reviewing the pathogenesis of antibody-mediated rejection and renal graft pathology after kidney transplantation. Morozumi K, Takeda A, Otsuka Y, Horike K, Gotoh N, Narumi S, Watarai Y, Kobayashi T. *Nephrology (Carlton).* 2016 Jul;21

22. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 1: update on national regulatory frameworks pertinent to clinical islet xenotransplantation. Cozzi E, Tönjes RR, Gianello P, Bühler LH, Rayat GR, Matsumoto S, Park CG, Kwon I, Wang W, O'Connell P, Jessamine S, Elliott RB, Kobayashi T, Hering BJ. *Xenotransplantation*. 2016 Jan-Feb;23(1):14-24.

23. Association of Dialysis Duration with Outcomes after Transplantation in a Japanese Cohort. Goto N, Okada M, Yamamoto T, Tsujita M, Hiramitsu T, Narumi S, Katayama A, Kobayashi T, Uchida K, Watarai Y. *Clin J Am Soc Nephrol*. 2016 Mar 7;11(3):497-504.

24. De Novo Anti-HLA DSA Characteristics and Subclinical Antibody-Mediated Kidney Allograft Injury. Yamamoto T, Watarai Y, Takeda A, Tsujita M, Hiramitsu T, Goto N, Narumi S, Katayama A, Morozumi K, Uchida K, Kobayashi T. *Transplantation*. 2016 Oct;100(10):2194-202.

25. Impact of Arterial Reconstruction With Recipient's Own Internal Iliac Artery for Multiple Graft Arteries on Living Donor Kidney Transplantation: Strobe Study. Hiramitsu T, Futamura K, Okada M, Yamamoto T, Tsujita M, Goto N, Narumi S, Watarai Y, Kobayashi T. *Medicine (Baltimore)*. 2015 Oct;94(43):e1811.

26. Current status of pig kidney xenotransplantation. Iwase H, Kobayashi T. *Int J Surg*. 2015 Nov;23(Pt B):229-233.

27. Impact of arterial reconstruction with recipient's own internal iliac artery for multiple graft arteries on living donor kidney transplantation: STROBE study. Hiramitsu T, Futamura K, Okada M, Yamamoto T, Tsujita M, Goto N, Narumi S, Watarai Y, Kobayashi T. *Medicine (Baltimore)*. 2015 Oct;94(43):e1811.
28. A proliferation-inducing ligand sustains the proliferation of human naïve (CD27⁻) B cells and mediates their differentiation into long-lived plasma cells in vitro via transmembrane activator and calcium modulator and cyclophilin ligand interactor and B-cell mature antigen. Matsuda Y, Haneda M, kadomatsu K, Kobayashi T. *Cell Immunol*. 2015 Jun;295(2):127-36.
29. Virus-associated hemophagocytic syndrome in renal transplant recipients: report of 2 cases from a single center. Nanmoku K, Yamamoto T, Tsujita M, Hiramitsu T, Goto N, Katayama A, Narumi S, Watarai Y, Kobayashi T, Uchida K. *Case Rep Hematol*. 2015;2015:876301.
30. Beneficial effects of preemptive kidney transplantation on calcium and phosphorus disorders in early post-transplant recipients. Tsujita M, Inaguma D, Goto N, Yamamoto T, Hiramitsu T, Katayama A, Takeda A, Kobayashi T, Morozumi K, Uchida K, Narumi S, Watarai Y, Tominaga Y. *Clin Exp Nephrol*. 2015 Apr;19
31. Functional difference between membrane-bound and soluble human thrombomodulin. Miwa Y, Yazaki S, Iwamoto M, Suzuki S, Iwasaki K, Haneda M, Yamamoto K, Maruyama S, Onishi A, Kobayashi T. *Transplantation*. 2015 Apr;99(4):702-9.

和文論文

1. 岩崎研太、三輪祐子、打田和治、堀見孔星、松岡裕、村口篤、岸裕幸、浜名洋、小林孝彰 「内皮細胞 HLA-class II DR とアロ応答する CD4 T 細胞は、anti-A/B 抗体接着により抑制される」 2018 MHC (組織適合性学会賞受賞)
2. 小林孝彰 「異種移植への期待：臨床試験に向けての課題と最近の動向」 医学のあゆみ 2017 263 192-200
3. 小林孝彰 「日本の腎移植事情と愛知医大の取り組み」現代医学 2016
4. 小林孝彰 「腎と透析診療指針 2016 テーマ【第 18 章 腎移植】 16. 既存抗体陽性例の腎移植」 腎と透析 2016 vol180 増刊号 754-756
5. 岩崎研太、小林孝彰 「免疫順応」病理と臨床 2015 34 巻 2 号